| Document |
Document Title |
|
WO/2024/097629A1 |
The present disclosure relates to compounds of Formula (I): or pharmaceutically acceptable salts or isotopically labeled derivatives thereof, wherein A is a 6- to 10- membered bridged bicyclic heterocycloalkyl comprising at least one oxy...
|
|
WO/2024/097229A1 |
Disclosed herein are methods, compounds, and compositions for treating or preventing inflammasome-mediated dermatological diseases or conditions.
|
|
WO/2024/097347A1 |
In some embodiments provided herein are methods of administering an adductor canal block in a patient, wherein the methods include: (a) selecting an entry point of an injection needle in a leg of the patient; (b) inserting the injection ...
|
|
WO/2024/097415A1 |
A tumescent solution including: a vasoconstrictor; a B vitamin and a pharmaceutically acceptable carrier. In some examples, the tumescent solution further includes a drug or therapeutic agent dissolved in the tumescent solution. Some exa...
|
|
WO/2024/096418A1 |
The present invention relates to a pharmaceutical or cosmetics composition having anti-inflammatory, anti-pruritic, anti-allergenic, and deodorant effect, the composition comprising composite extract of Lagerstroemia indica and Persicari...
|
|
WO/2024/097814A1 |
The invention provides methods for upregulating mitochondrial and/or glycolytic metabolism in T cells by increasing the flux of pyruvate into the citric acid cycle, thereby increasing mitochondrial and/or glycolytic metabolism. In genera...
|
|
WO/2024/095005A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof: wherein V, W, X, Y, Z, A1, A2, A3, A4, A5, A6, A7, A8, A9 and R3 are as defined in the specification,...
|
|
WO/2024/096067A1 |
Provided is a cyclic peptide derivative composition for treating or preventing neuropathic pain and/or inflammatory pain. The present disclosure pertains to a composition containing: a compound for treating or preventing neuropathic pa...
|
|
WO/2024/093625A1 |
The present invention relates to the technical field of biomedicine. Disclosed is a linolenic acid-derived ceramide, which has a structure of general formula I or an isomer of general formula I: (I), wherein R1 is selected from (II) or (...
|
|
WO/2024/096261A1 |
The present invention relates to a pharmaceutical composition for treating or preventing autoinflammatory diseases, comprising, as an active ingredient, TLR inhibitor peptide 1 (TIP-1) or MAL/MyD88 inhibitory peptide 2 (MIP-2) or a polyn...
|
|
WO/2024/092888A1 |
Provided is use of an anti-angiopoietin-like protein 4 antibody in the preparation of a drug for inhibiting the expression of an inflammatory factor. By constructing a mouse animal model of collagen-induced arthritis (CIA) to stimulate t...
|
|
WO/2024/096121A1 |
The present disclosure provides a bacterial preparation that can be used to treat inflammatory bowel disease. More specifically, the present disclosure relates to a microorganism in which a gene from at least one of a fimbria operon gene...
|
|
WO/2024/044666A3 |
Methods of stimulating production of specialized pro-resolving mediators (SPMs) by mesenchymal stem cells (MSCs) are provided. The methods include contacting MSCs with one or more SPM fatty acid precursors, SPM intermediates, or a combin...
|
|
WO/2024/095268A1 |
Methods for treating or reducing inflammation, in is in a site or an organ excluding the central nervous system of a subject in need thereof, by administering a pharmaceutical composition comprising the translocator protein ligand 2-C1-M...
|
|
WO/2024/069007A3 |
The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, diastereoisomer, enantiomer, polymorph, racemic mixture, solvate or isomers and mixtures thereof. The invention further relat...
|
|
WO/2024/096569A1 |
The present invention relates to a composition, more preferably, a transdermally- or topically-administered composition, comprising, as an active ingredient, a thienopyridine compound of chemical formula 1 or a pharmaceutically acceptabl...
|
|
WO/2024/097694A1 |
The disclosure is directed to improved methods of treating minor pain in humans using a pharmaceutical dosage form comprising acetaminophen in admixture with naproxen.
|
|
WO/2024/095003A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof: Formula (I) wherein Z, X, R1, R2, R4, R5, R6 and R7 are as defined in the specification, processes fo...
|
|
WO/2024/089179A1 |
Use of dairy lipid to lower the GlycA level in a subject.
|
|
WO/2024/088311A1 |
The present invention belongs to the technical field of medicine, and specifically relates to a crystal form of an imidazopyrazine derivative represented by formula (I), a preparation method therefor and a use thereof.
|
|
WO/2024/091701A1 |
Provided herein are compositions and methods for tissue repair. In particular, the compositions and methods described herein find use in repairing, regenerating, and modulating fibrosis and inflammation in a variety of tissues such as, f...
|
|
WO/2024/090941A1 |
The present invention relates to a composition for the prevention, amelioration or treatment of an anterior segment eye disease, the composition comprising a plant extract of the genus Aloe as an active ingredient. When the Aloe vera ext...
|
|
WO/2024/088922A1 |
The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L, W, Y, Z, and R1 to R3 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods o...
|
|
WO/2024/088109A1 |
Provided are an aryl heterocyclic compound, a preparation method therefor, and a use thereof, and the structural formula of the aryl heterocyclic compound is as shown in formula (I). The provided compound has a monoaminergic system regul...
|
|
WO/2024/092069A1 |
The present invention provides CXCR4 inhibitors of Formula (I): and pharmaceutically acceptable salts thereof, and methods for their use in treating neurological and CNS diseases, disorders, and conditions.
|
|
WO/2024/092269A1 |
The present invention relates to pharmaceutical formulations for kratom extract and mitragynine, which is the major alkaloid extracted from kratom, and use methods thereof for treatment of osteoarthritis in canine subjects.
|
|
WO/2024/091983A1 |
The present invention relates to novel compounds and compositions thereof. The compositions are useful in the treatment of an epithelial or endothelial barrier dysfunction disorder in a subject.
|
|
WO/2024/040206A9 |
The present disclosure relates to novel PD-1 agonist antibodies and methods and uses of anti-human PD-1 agonist antibodies for the treatment of autoinflammatory and/or autoimmune diseases. Also provided are doses and dosing regimens for ...
|
|
WO/2024/086919A1 |
The present disclosure provides antibodies or antigen-binding fragments thereof that bind specifically to integrin α11 (ITGA11). This disclosure also provides methods for treating a disorder in a subject, such as a fibrotic disorder, an...
|
|
WO/2024/090606A1 |
The present invention provides a method for treating posterior scleritis, comprising a first step of administering a steroid to a posterior scleritis patient through an intravenous injection, and a second step of orally administering a s...
|
|
WO/2024/090329A1 |
The present inventors have found that a pyridoxal synthetic enzyme Pyridoxamine-5'-phosphate oxidase (PNPO) acts as an oxygen sensing mechanism for a novel pathway that is independent from an HIF pathway in chronic hypoxia. A pharmaceuti...
|
|
WO/2024/091523A1 |
The present disclosure relates in some aspects to certain phenethylamine analogs, such as benzocyclobutene and benzocyclopentene analogs, including those of Formula (1). Also provided are methods of synthesizing the compounds, compositio...
|
|
WO/2024/088307A1 |
Disclosed are a novel peptidyl nitrile compound and a use thereof, and specifically disclosed are a compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound and/or th...
|
|
WO/2024/091148A2 |
The invention relates to the chemical and pharmaceutical industry, and more particularly to a liquid balneological concentrate for preparing health-giving and therapeutic full or partial baths at health resorts and in other medical and w...
|
|
WO/2024/088110A1 |
Provided are a heterocyclic macrocyclic compound containing an indazole structure and used as a protein kinase inhibitor, and a preparation method therefor. The compound has the structure represented by general formula (I). Additionally ...
|
|
WO/2024/090469A1 |
The present invention addresses the problem of providing a pharmaceutical composition, particularly a compound that is suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases. The inventors of th...
|
|
WO/2024/089421A1 |
The invention relates to compounds of formula (I) and related aspects.
|
|
WO/2024/091664A1 |
This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain examples, modulators are derivatives of hexahydropental ene. In certain examples, this...
|
|
WO/2024/090571A1 |
Provided are: a method for detecting immune-mediated inflammatory diseases characterized by an increase in the expression of MMP12 in a subject; a diagnostic drug containing a substance that specifically interacts with MMP12; and a thera...
|
|
WO/2024/089046A1 |
The present invention relates to a pharmaceutical composition suitable for an intra-articular injection comprising an anesthetic agent and an immediate or controlled release dosage form comprising colchicine. It further relates to a phar...
|
|
WO/2024/090538A1 |
The present invention relates to a pharmaceutical composition for the treatment or prevention of inflammatory bowel diseases, said pharmaceutical composition containing zinc polyphosphate as an active ingredient. The zinc polyphosphate i...
|
|
WO/2024/090537A1 |
The present invention relates to a novel zinc polyphosphate, a use thereof, and a method for producing the same. More specifically, the present invention relates to: a zinc polyphosphate which is characterized by showing a halo peak at 2...
|
|
WO/2024/082917A1 |
Disclosed are a crystal form A of bupivacaine-meloxicam salt, a single crystal thereof, a preparation method therefor and a use thereof. An X-ray powder diffraction pattern of the crystal form A of the bupivacaine-meloxicam salt has char...
|
|
WO/2024/085558A1 |
The present invention relates to a composition for preventing or treating OSCAR-induced diseases, containing brivudine as an active ingredient, and a method for treating OSCAR-induced diseases, comprising the step of administering the co...
|
|
WO/2024/085557A1 |
The present invention relates to: a composition for preventing or treating OSCAR-induced diseases, comprising comprising adefovir as an active ingredient; and a method for treating OSCAR-induced diseases, comprising a step of administeri...
|
|
WO/2024/085081A1 |
Provided is an antibody that specifically binds to the extracellular domain of human LPA1 but does not specifically bind to the extracellular domain of human LPA2 or the extracellular domain of human LPA3. The antibody preferably has act...
|
|
WO/2024/085623A1 |
The present invention relates to a microbiome composition of a fermentation culture supernatant of Lactiplantibacillus plantarum strain KM2 having an anti-inflammatory effect. It has been confirmed that the fermentation culture supernata...
|
|
WO/2024/085698A1 |
The present invention provides a pharmaceutical composition for the prevention or treatment of inflammatory bowel disease, comprising a glycogen phosphorylase (PYGL) inhibitor as an active ingredient, and a method for screening for a mat...
|
|
WO/2024/085581A1 |
The present invention relates to a sustained-release injectable composition for treating or preventing an inflammatory disease, and to a method for preparing same. The present invention may continuously release cannabidiol for more than ...
|
|
WO/2024/082014A1 |
The present invention relates to compositions comprising cannabidiolic acid and fatty acids; pharmaceuticals, nutraceuticals, medical foods, dietary supplements, functional foods, animal foods and dosage forms comprising this composition...
|
